InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mornings like we had on Wednesday are exactly why I get up and ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...

Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its ...

Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack.

HealthInvest showcased ASX-listed healthcare companies where scientific innovation, commercial opportunity and patient outcomes align.

As part of the campaign, AKF has enhanced its webpage on FSGS with expanded information on diagnosis, treatment options and types of FSGS. AKF also created accompanying digital guides for patients on ...

In its largest acquisition to date, Incyte Inc. snagged rights to phase III-stage VGA-039, a monoclonal antibody the firm said could offer a new standard of care in von Willebrand disease (VWD), in a ...

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...

Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.

Endothelin biology remains an attractive therapeutic target in IgA nephropathy where intrarenal endothelin-1 expression is upregulated and implicated in nephron loss through vasoconstriction, ...

June 2 (Reuters) - Travere Therapeutics (TVTX.O), opens new tab said on Tuesday it has signed a licensing pact with privately held biotech Everest Medicines to develop and ‌commercialize an ...

Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech ​Everest Medicines to develop and commercialize ‌an experimental kidney disease drug in a deal worth up ...